This Case is about FINANCIAL ANALYSIS
PUBLICATION DATE: December 01, 2009 PRODUCT #: 909E20-HCB-ENG
The Challenge of Access to Oncology Drugs in Canada case solution
Recently, many states with publicly funded health care have began using cost-effectiveness analysis (CEA) along with review of clinical data as a tool to evaluate the entire gain of a brand new drug to the society and establish precedence with regards to medical care budget. Cost effectiveness was officially integrated into the Ontario drug review system in 1993 and the Canadian drug-review system in 2003. The problem of using cost effectiveness has gotten increasingly controversial in recent years: that they were frequently classified as being cost effective. Costs although some recently approved cancer drugs cost $3,000 to $6,000 or more for one treatment cycle. This note reviews many of the contending interests in predicaments about health care lending choices in the existence of limited budgets and discussions over drug funding.